Replimune Group heads into its September 15 earnings report with a sharp disconnect: short interest is near a one-month high, yet analysts have been upgrading the stock in a cluster rarely seen for a name with this much regulatory overhang.
The short-side pressure is real and growing. Short interest has climbed to 34.4% of the free float — up 43% over the past month, with the bulk of that build coming in the second half of August. FINRA's most recent fortnightly settlement data put short shares at roughly 24.9 million, implying nearly four days to cover. That is a heavy position for a $15.80 stock. What makes it striking, though, is how cheap and accessible the borrow remains: cost to borrow is below 0.5%, down sharply from the 1.06% seen earlier this month, and availability is a loose 603% — meaning shares are readily available to borrow despite the elevated short base. The lending market is not signalling squeeze pressure. Options, however, tell a different story: the put/call ratio has collapsed to just 0.32, more than 2.5 standard deviations below its 20-day average of 0.76. That is one of the most call-skewed readings of the past year. Taken together, the setup shows a market split down the middle — shorts rebuilding aggressively on the register while call buyers pile in on the options side, each camp betting on opposite outcomes into earnings.
The Street has been moving clearly in one direction. JP Morgan raised its target to $21 — the second lift in three weeks — while maintaining its Overweight rating, which at the current $15.80 price implies meaningful upside to consensus. Wedbush upgraded to Outperform in early August and more than doubled its target to $19. Leerink Partners followed suit, also upgrading and lifting its target from $11 to $17. The consensus mean price target is $19.50, roughly 23% above where the stock trades. On the factor side, analyst recommendation momentum scores in the 100th percentile — the most constructive reading in the universe — while EPS forward estimate momentum ranks in the 89th percentile. The bull case rests on Replimune's RPx oncolytic immunotherapy platform and a fresh FDA review team assigned to its RP1 BLA resubmission; bears point to the FDA's trial design concerns on the IGNYTE-3 study and an interim overall survival readout not expected until 2027, which extends the period of cash-burn uncertainty.
Institutional flows add colour to the bull side of the ledger. Ridgeback Capital Management established a 7.76% stake — its entire position initiated fresh — while Montanova Capital added roughly 5.6 million shares to bring its holding above 7% of shares outstanding. Both moves were reported recently and represent significant new conviction. BlackRock added 2.7 million shares, and Goldman Sachs more than doubled its position. Against that, insiders were net sellers in August: the CEO sold roughly 39,000 shares at $12.97 on August 10, with the CFO and CMO also selling on the same day. Those were likely planned-sale disposals rather than negative signals — the stock has since rallied above $15 — but the net 90-day insider balance is modestly negative in dollar terms.
The price action itself has been dramatic. REPL is up 63% over the past month and 7.4% in the last session alone, against a mixed peer backdrop: QURE gained 7.7% on the week while CADL added 12.9%, but CURAS fell nearly 7%. REPL has clearly been the standout mover in its corner of the biotech space. The next focal point is the September 15 earnings event, where the interplay between the FDA resubmission timeline, cash runway disclosures, and any update on the IGNYTE-3 interim data schedule will determine whether the Street's freshly upgraded targets hold or the sizeable short base finds vindication.
See the live data behind this article on ORTEX.
Open REPL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
